Small molecule inducers of neurotrophic function

IDrugs

Volumn 1, Issue 4, 1998, Pages 452-455

  Wood, Paul L ^a  

^a Neurex Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0342979464     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Walsh G: Nervous excitement over neurotrophic factors. Biotechnology (1995) 13:1167-1171.
2. Hudkins RL: New horizons in Alzheimer's disease therapy: Neurotrophin-like small molecules. Alzheimer's Disease ID Research Alert (1997) 2:407-416.
3. 1A receptor agonist. Fundam and Clin Pharmacol (1993) 7:413-427.
4. 1A receptor agonist. Fund Clin Pharmacol (1993) 7:487-497.
5. 1A receptors. Eur J Pharmacol (1994) 253:139-147.
6. Pradines A, Magazin M, Schiltz P, Le Fur G, Caput D, Ferrara P: Evidence for nerve growth factor-poten-tiating activities of the nonpeptidic compound SR-57746A in PC12 cells. J Neurochem (1995) 64:1954-1964.
7. Ruift GSF, Makkink WK, Konings PNM: SR-57746A attenuates cytostatic drug-induced reduction of neurite outgrowth in co-cultures of rat dorsal root ganglia and Schwann cells. Neurosci Lett (1996) 203:9-12.
8. Roux S, Hubert I, Wettstein JG, Soubrié P, Le Fur G, Porsolt RD: Facilitating effects of SR-57746A on short-term memory in an operant delayed alternation task in aged rats. Drug Dev Res (1995) 35:83-93.
9. Fournier J, Steinberg R, Gauthier T, Keane PE, Guzzi U, Coudé FX, Bougault I, Maffrand JP, Soubrié P, Le Fur G: Protective effects of SR-57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience (1993) 55:629-641.
10. Terranova JP, Kan JP, Storme JJ, Perreaut P, LeFur G, Soubrie P: Administration of amyloid β-peptides in the rat medial septum causes memory deficits: reversal by SR-57746A, a non-peptide neurotrophic compound. Neurosci Lett (1996) 213:79-82.
11. Fournier J, Keane PE, Ferrara P, Soubrie P: SR-57746A: An orally active non-peptide compound with neurotrophic and neuroprotective effects. CNS Drug Rev (1997) 3:147-166.
12. AIT-082. Drugs Future (1997) 22:945-947.
13. Middlemiss PJ, Glasky AJ, Rathbone MP, Werstuik E, Hindley S, Gysbers J: AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells. Neurosci Lett (1995) 199:131-134.
14. Glasky AJ, Glasky MS, Ritzmann RF, Rathbone MP: AIT-082, a novel purine derivative with neuroregenerative properties. Exp Opin Invest Drugs (1997) 6: 1413-1417.
15. Glasky AJ, Melchior CL, Pirzadeh B, Heydari N, Ritzmann RF: Effect of AIT-082, a purine analog, on working memory in normal and aged mice. Pharmacol Biochem Behav (1994) 47:325-329.
16. Wakita H, Tomimoto H, Akiguchi I, Kimura J: Protective effect of cyclosporin A on white matter changes in the rat brain after chronic hypoperfusion. Stroke (1995) 26: 1415-1422.
17. Uchino H, Elmér E, Uchino K, Lindvall O, Siesjö BK: Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat. Acta Physiol Scand (1995) 155: 469-471.
18. Kondo Y, Ogawa N, Asanuma M, Nishibayashi S, Iwata E, Mori A: Cyclosporin A prevents ischemia-induced reduction of muscarinic acetylcholine receptors with suppression of microglial activation in gerbil hippocampus. Neurosci Res (1995) 22:123-127.
19. Paul C, Bolton C: Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-term therapy with dexamethasone or cyclosporin A. Int J Immunopharm (1995) 17:497-503.
20. Sharkey J, Butcher SP: Immunophillins mediate the neuroprotective effects of FK-506 in focal ischemia. Nature (1994) 371:336-339.
21. Sharkey J, Crawford JH, Butcher SP, Marston HM: Tacrolimus (FK-506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. Stroke (1996) 27:2282-2286.
22. Ide T, Morikawa E, Kirino T: An immunosuppressant, FK-506, protects hippocampal neurons from forebrain ischemia in the Mongolian gerbil. Neurosci Lett (1996) 204:157-160.
23. Tanaka K, Fukuuchi Y, Nozaki H, Nagata E, Kondo T, Koyama S, Dembo T: Calclneurin inhibitor, FK-506, prevents reduction in the binding capacity of cyclic AMP-dependent protein kinase in ischemic gerbil brain. J Cereb Blood Flow Metab (1997) 17:412-420.
24. Tokime T, Nozaki K, Kikuchi H: Neuroprotective effect of FK-506, an immunosuppressant, on transient global ischemia in gerbil. Neurosci Lett (1996) 206:81-84.
25. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH: Immunosuppressant FK-506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA (1993) 90:9808-9812.
26. Gold BG, Storm-Dickerson T, Austin DR: The immunosuppressant FK-506 increases functional recovery and nerve regeneration following peripheral nerve injury. Rest Neurol Neurosci (1994) 6:287-296.
27. Gold BG, Katoh K, Storm-Dickerson T: The immunosuppressant FK-506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci (1995) 15:7509-7516.
28. Butcher SP, Henshall DC, Teramura Y, Iwasaki K, Sharkey J: Neuroprotective actions of FK-506 in experimental stroke: In vivo evidence against an antiexcitotoxic mechanism. J Neurosci (1997) 17:6939-6946.
29. Lyons WE, Steiner JP, Snyder SH, Dawson TM: Neuronal regeneration enhances the expression of the immunophilin FKBP-12. J Neurosci (1995) 15:2985-2994.
30. Sabatini DM, Lai MM, Snyder SH: Neural roles of immunophilins and their ligands. Mol Neurobiol (1997) 15:223-239.
31. Steiner JP, Connolly MA, Valentine HI, Hamilton GS, Dawson TM, Hester L, Snyder SH: Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK-506, rapamycin and cyclosporin A. Nat Med (1997) 3:421-428.
32. Wang MS, Zeleny-Pooley M, Gold BG: Comparative dose-dependence study of FK-506 and cyclosporin a on the rate of axonal regeneration in the rat sciatic nerve. J Pharmacol Exp Ther (1997) 282:1084-1093.
33. Dumont FJ, Staruch MJ, Koprak SL: The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med (1992) 176:751-760.
34. Sinclair PJ, Wong F, Staruch MJ, Wiederrecht G, Parsons WH, Dumont F, Wyvratt M: Preparation and in vitro activities of naphthyl and indolyl ether derivatives of the FK-506 related immunosuppressive macrolide ascomycin. Bioorg Med Chem Lett (1996) 6:2193-2196.
35. Hamilton GS, Huang W, Connolly MA, Ross DT, Guo H, Valentine HL, Suzdak PD, Steiner JP: FKBP12-binding domain analogues of FK-506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of Parkinson's disease. Bioorg Med Chem Lett (1997) 7:1785-1790.
36. Gold BG, Zeleny-Pooley M, Wang MS, Chaturvedi P, Armistead DM: A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp Neurol (1997) 147:269-278.
37. Costantini LC, Chaturvedi P, McCaffrey P, Deacon TW, Isacson O: Neuroprotective and regenerative effects of immunophilin ligands in an animal model of Parkinson's disease. Soc Neurosci Abst (1997) 27:P573.11.